JANSSEN ABIRATERONE abiraterone acetate 250 mg tablet bottle

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

abiraterone acetate, Quantity: 250 mg

Dostępny od:

Janssen-Cilag Pty Ltd

INN (International Nazwa):

Abiraterone acetate

Forma farmaceutyczna:

Tablet

Skład:

Excipient Ingredients: colloidal anhydrous silica; povidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; croscarmellose sodium

Droga podania:

Oral

Sztuk w opakowaniu:

120 tablets

Typ recepty:

(S4) Prescription Only Medicine

Wskazania:

JANSSEN ABIRATERONE is indicated in combination with prednisone or prednisolone for the treatment of: ? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT), or ? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) or ? patients with mCRPC who have received prior chemotherapy containing a taxane.

Podsumowanie produktu:

Visual Identification: White to off-white, oval shaped tablets with "AA250" on one side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status autoryzacji:

Registered

Data autoryzacji:

2012-03-01